Anzeige
Mehr »
Dienstag, 19.08.2025 - Börsentäglich über 12.000 News
6,35-Mrd. vs. 30-Mio.-€ - Die Bewertungslücke im Kohlesektor, die kein Investor ignorieren kann
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PV0Q | ISIN: CA87975M2085 | Ticker-Symbol: 3D0A
Frankfurt
18.08.25 | 08:04
0,014 Euro
0,00 % 0,000
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
TELO GENOMICS CORP Chart 1 Jahr
5-Tage-Chart
TELO GENOMICS CORP 5-Tage-Chart
RealtimeGeldBriefZeit
0,0390,05807:49
0,0450,04907:30

Aktuelle News zur TELO GENOMICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
05.08.Telo Genomics Corp.: Telo Genomics to Present at the OTCQB Venture Virtual Investor Conference382Toronto, Ontario--(Newsfile Corp. - August 5, 2025) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") a leader in the development of diagnostic and prognostic tests for human...
► Artikel lesen
24.07.Telo Genomics Corp.: International Myeloma Society Accepts Telo Genomics' MRD Abstract for Presentation at Its 2025 Meeting317Toronto, Ontario--(Newsfile Corp. - July 24, 2025) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") a leader in the development of diagnostic and prognostic tests for human...
► Artikel lesen
01.07.Telo Genomics Corp (2): Telo Genomics used by ex-president Louis over bonuses8
01.07.Telo Genomics Corp. to File Statement of Defence and Counterclaim to Lawsuit Filed by Former President309Toronto, Ontario--(Newsfile Corp. - June 30, 2025) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo Genomics") has received a Statement of Claim filed by Sherif Louis, the...
► Artikel lesen
19.06.Telo Genomics Corp (2): Telo Genomics begins multiple myeloma clinical trial1
TELO GENOMICS Aktie jetzt für 0€ handeln
18.06.Telo Genomics Corp.: Telo Genomics Initiate Clinical Trial for Minimal Residual Disease in Multiple Myeloma378Toronto, Ontario--(Newsfile Corp. - June 18, 2025) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo"), a leader in the development of diagnostic and prognostic tests for human...
► Artikel lesen
28.05.Telo Genomics Corp (2): Telo Genomics enters client agreement with IPON4
27.05.Telo Genomics Corp.: Telo Genomics Receives New Client Tier under Intellectual Property Ontario (IPON)375Toronto, Ontario--(Newsfile Corp. - May 27, 2025) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") a leader in the development of diagnostic and prognostic tests for human...
► Artikel lesen
15.05.Telo Genomics Corp.: European Hematology Association Accepts Abstract from Telo Genomics for Presentation at The 2025 Congress478Toronto, Ontario--(Newsfile Corp. - May 15, 2025) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") a leader in the development of diagnostic and prognostic tests for human...
► Artikel lesen
10.04.Telo Genomics Corp.: Telo Genomics Announces Acceptance of its MRD Validation Data in Multiple Myeloma for ASCO 2025539Toronto, Ontario--(Newsfile Corp. - April 10, 2025) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo"), a leader in the development of diagnostic and prognostic tests for human...
► Artikel lesen
04.04.Telo Genomics Corp (2): Telo Genomics appoints Farlinger as director3
04.04.Telo Genomics Corp.: Telo Genomics Announces Appointment of John Farlinger to Its Board of Directors396Toronto, Ontario--(Newsfile Corp. - April 4, 2025) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo Genomics") a leader in the development of diagnostic and prognostic tests...
► Artikel lesen
12.03.Telo Genomics Corp (2): Telo Genomics appoints Baechler as executive chairman4
12.03.Telo Genomics appoints Baechler executive chairman of the board of directors4
12.03.Telo Genomics Corp.: Telo Genomics Appoints Baechler Executive Chairman of The Board of Directors373Toronto, Ontario--(Newsfile Corp. - March 12, 2025) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo Genomics") a leader in the development of diagnostic and prognostic tests...
► Artikel lesen
27.02.Telo Genomics Corp.: Telo Genomics Announces Expanded Partnership with Trusted Health Advisors546Toronto, Ontario--(Newsfile Corp. - February 27, 2025) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo Genomics") announces that, further to its engagement with Trusted Health...
► Artikel lesen
23.12.24Telo Genomics Corp.: Telo Genomics Closes Oversubscribed $2.5 Million Private Placement695Toronto, Ontario--(Newsfile Corp. - December 23, 2024) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (FSE: 3DOA) (the "Company" or "Telo") is pleased to announce that, further to its news release...
► Artikel lesen
12.12.24Telo Genomics Corp.: Telo Genomics Announces Private Placement for up to $2 Million627Toronto, Ontario--(Newsfile Corp. - December 12, 2024) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (FSE: 3DOA) (the "Company" or "Telo") is pleased to announce a non-brokered private placement...
► Artikel lesen
19.11.24Telo Genomics Corp.: Telo Genomics Receives Approval from the Intellectual Property Ontario Program (IPON)418Toronto, Ontario--(Newsfile Corp. - November 19, 2024) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") a biotech company developing the industry's leading telomere technology...
► Artikel lesen
30.10.24Telo Genomics Corp.: Telo Genomics Expands its Strategic Collaboration with Mayo Clinic398Toronto, Ontario--(Newsfile Corp. - October 30, 2024) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") a biotech company developing the industry's leading telomere technology...
► Artikel lesen
Weiter >>
22 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1